<?xml version="1.0" encoding="UTF-8"?>
<ref id="B158-molecules-26-00431">
 <label>158.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Lockhart</surname>
    <given-names>A.C.</given-names>
   </name>
   <name>
    <surname>Calvo</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Tolcher</surname>
    <given-names>A.W.</given-names>
   </name>
   <name>
    <surname>Rowinsky</surname>
    <given-names>E.K.</given-names>
   </name>
   <name>
    <surname>Shackleton</surname>
    <given-names>G.</given-names>
   </name>
   <name>
    <surname>Morrison</surname>
    <given-names>J.G.</given-names>
   </name>
   <name>
    <surname>Rafi</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>VerMeulen</surname>
    <given-names>W.</given-names>
   </name>
   <name>
    <surname>Rothenberg</surname>
    <given-names>M.L.</given-names>
   </name>
  </person-group>
  <article-title>A Phase I Dose-Escalation Study of SR271425, an Intravenously Dosed Thioxanthone Analog, Administered Weekly in Patients With Refractory Solid Tumors</article-title>
  <source>Am. J. Clin. Oncol.</source>
  <year>2009</year>
  <volume>32</volume>
  <fpage>9</fpage>
  <lpage>14</lpage>
  <pub-id pub-id-type="doi">10.1097/COC.0b013e318178331b</pub-id>
  <pub-id pub-id-type="pmid">19194116</pub-id>
 </element-citation>
</ref>
